Gideon Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gideon Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,416	Closed	-$677K	–	258
2019 Q3	$677K	Buy	+8,416	New	+$666K	0.22%	151
2018 Q4	–	Sell	-6,404	Closed	-$560K	–	362
2018 Q3	$560K	Buy	6,404 +2,814	+78%	+$283K	0.26%	121
2018 Q2	$354K	Sell	3,590 -3,395	-49%	-$337K	0.18%	220
2018 Q1	$832K	Buy	+6,985	New	+$901K	0.52%	31

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Gideon Capital Advisors's ALNY Position: Q4 2019 in Review

Gideon Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2019, closing a stake of 8,416 shares — an estimated $677K sold.

Gideon Capital Advisors first reported a position in ALNY in Q1 2018 and held it in 4 quarters. The position peaked at $832K in Q1 2018. 316 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

Gideon Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Gideon Capital Advisors sold 8,416 Alnylam Pharmaceuticals shares in Q4 2019, an estimated $677K.
Gideon Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Gideon Capital Advisors's Alnylam Pharmaceuticals position peaked at $832K in Q1 2018.
316 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Gideon Capital Advisors's 13F filing for Q4 2019, filed 11 Feb 2020.